Physician profile
Maan Jamal
NPI 1326072471
$4,402.93
in general payments reported to CMS, 2019-2025
23 companies · $2,295 in 2025
The $2,295 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $1,148 · 2024: $800 · 2025: $2,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,280.13 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $610.12 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Verona Pharma, INC. | $606.92 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $424.65 | 2023-2025 | Dupixent |
| Amgen INC. | $286.23 | 2023-2025 | Repatha, Tezspire, Otezla |
| Insmed, INC. | $195.48 | 2025 | Arikayce, Brinsupri |
| Novo Nordisk INC | $158.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $135.54 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $113.92 | 2022-2025 | Rexulti |
| Abbvie INC. | $93.60 | 2025 | |
| Neurocrine Biosciences, INC. | $63.22 | 2022-2023 | Ingrezza |
| Viatris Specialty LLC | $56.89 | 2025 | Yupelri |
| Inogen, INC. | $55.41 | 2023-2025 | Inogen, Inogen One G5 Oxygen Concentrator - Bluetooth |
| Actelion Pharmaceuticals US, INC. | $51.97 | 2024 | Opsumit, Uptravi |
| Lilly USA, LLC | $47.44 | 2024-2025 | Zepbound, Mounjaro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.33 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $37.73 | 2023 | Austedo Xr |
| Acadia Pharmaceuticals INC | $35.93 | 2023-2024 | Nuplazid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.58 | 2024-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $21.98 | 2023 | Yupelri |
| Exact Sciences Corporation | $19.56 | 2025 | The Cologuard Plus Collection Kit |
| Inari Medical, INC. | $14.04 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maan Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.